Changing patterns in the neuropathogenesis of HIV during the HAART era

Brain Pathology

Volumn 13, Issue 2, 2003, Pages 195-210

  Langford, T D ^a   Letendre, S L ^b   Larrea, G J ^c   Masliah, E ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RESRIPTOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VALSPODAR; VERAPAMIL; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; ANEMIA; ASTROCYTE; ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN MITOCHONDRION; CARDIOVASCULAR RISK; CELL DAMAGE; CELL INFILTRATION; CLINICAL TRIAL; CONFERENCE PAPER; DEMENTIA; DEMYELINATION; DISEASE ACTIVITY; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG TRANSPORT; DYSLIPIDEMIA; ENCEPHALITIS; GRANULOCYTOPENIA; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY; HYPERTENSION; INCIDENCE; LACTIC ACIDOSIS; LIPID METABOLISM; LIPODYSTROPHY; METABOLIC DISORDER; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOGENESIS; PREVALENCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SIDE EFFECT; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; VIRION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS VIRULENCE;

EID: 0344406085     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2003.tb00019.x     Document Type: Conference Paper

References (124)

1. Achim C, Wang R, Miners D, Wiley C (1994) Brain viral burden in HIV infection. J Neuropathol Exp Neurol 53:284-294.
2. Ammassari A, Cingolani A, Pezzotti P, De Luca DA, Murri R, Giancola ML, Larocca LM, Antinori A (2000) AIDS-related focal brain lesions in the era of highly active anti-retroviral therapy. Neurology 55:1194-1200.
3. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P (1995) The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332:488-493.
4. Aukrust P, Bjornsen S, Lunden B, Otterdal K, Ng EC, Ameln W, Ueland T, Muller F, Solum NO, Brosstad F et al (2000) Persistently elevated levels of von Willebrand factor antigen in HIV infection. Downregulation during highly active antiretroviral therapy. Thromb Haemost 84:183-187.
5. Bendayan R, Lee G, Bendayan M (2002) Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc Res Tech 57:365-380.
6. Blum MR, Liao SH, Good SS, de Miranda P (1988) Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 85:189-194.
7. Budka H, Wiley C, Kleihues P, Artigas J, Ashbury A, Cho E-S, Cornblath D (1991) HIV-associated disease of the nervous system: Review of nomenclature and proposal for neuropathology-based terminology. Brain Pathol 1:143-152.
8. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J (2001) The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 50:1378-1388.
9. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS et al (2000) Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 283:381-390.
10. Carr A, Cooper DA (2000) Adverse effects of antiretroviral therapy. Lancet 356:1423-1430.
11. Chariot P, Bourokba N, Brivet F (2002) Mitochondrial DNA and nucleoside toxicity. N Engl J Med 347:216-218; discussion 216-218.
12. Chiesi A, Vella S, Dally LG, Pedersen C, Danner S, Johnson AM, Schwander S, Goebel FD, Glauser M, Antunes F et al (1996) Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 11:39-44.
13. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB (2000) Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660.
14. Chun TW, Fauci AS (1999) Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A 96:10958-10961.
15. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 86:695-698.
16. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O'Shaughnessy MV et al (2002) Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 346:811-820.
17. Cui L, Locatelli L, Xie MY, Sommadossi JP (1997) Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells. J Pharmacol Exp Ther 280:1228-1234.
18. Dallasta L, Pisarov L, Esplen J, Werley J, Moses A, Nelson J, Achim C (1999) Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am J Pathol 155:1915-1927.
19. Darley-Usmar VM, Hogg N, O'Leary VJ, Wilson MT, Moncada S (1992) The simultaneous generation of superoxide and nitric oxide can initiate lipid peroxidation in human low density lipoprotein. Free Radic Res Commun 17:9-20.
20. Davies J, Everall I, Weich S, McLaughlin J, Scaravilli F, Lantos P (1997) HIV-associated brain pathology in the United Kingdom: an epidemiological study. AIDS 11:1145-1150.
21. De Clercq E (2002) New anti-HIV agents and targets. Med Res Rev 22:531-565.
22. De Clercq E (2002) New developments in anti-HIV chemotherapy. Biochim Biophys Acta 1587:258-275.
23. Demeule M, Jodoin J, Gingras D, Beliveau R (2000) P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries. FEBS Lett 466:219-224.
24. Deutsch R, Ellis RJ, McCutchan JA, Marcotte TD, Letendre S, Grant I (2001) AIDS-associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy. AIDS 15:1898-1899.
25. Dieleman JP, Jambroes M, Gyssens IC, Sturkenboom MC, Stricker BH, Mulder WM, de Wolf F, Weverling GJ, Lange JM, Reiss P et al (2002) Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS 16:737-745.
26. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ (1999) Changes to AIDS dementia comples in the era of highly active antiretroviral therapy. AIDS 13:1249-1253.
27. Drewe J, Gutmann H, Fricker G, Torok M, Beglinger C, Huwyler J (1999) HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 57:1147-1152.
28. Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, Atkinson JH, Grant I, Mallory M, Masliah E, Group tH (1999) Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. Brain Pathol 9:209-217.
29. Fenart L, Buee-Scherrer V, Descamps L, Duhem C, Poullain MG, Cecchelli R, Dehouck MP (1998) Inhibition of P-glycoprotein: rapid assessment of its implication in blood-brain barrier integrity and drug transport to the brain by an in vitro model of the blood-brain barrier. Pharm Res 15:993-1000.
30. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT et al (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 317:185-191.
31. Foudraine NA, Hoetelmans RM, Lange JM, de Wolf F, van Benthem BH, Maas JJ, Keet IP, Portegies P (1998) Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 351:1547-1551.
32. Garrigues A, Escargueil AE, Orlowski S (2002) The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci U S A 99:10347-10352.
33. Gartner S (2000) AIDS: HIV infection and dementia. Science 287:602.
34. Gendelman HE, Zheng J, Coulter CL, Ghorpade A, Che M, Thylin M, Rubocki R, Persidsky Y, Hahn F, Reinhard J, Jr. et al (1998) Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. J Infect Dis 178:1000-1007.
35. Giner V, Fernandez C, Esteban MJ, Galindo MJ, Forner MJ, Guix J, Redon J (2002) Reversible posterior leukoencephalopathy secondary to indinavir-induced hypertensive crisis: a case report. Am J Hypertens 15:465-467.
36. Glynn SL, Yazdanian M (1998) In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J Pharm Sci 87:306-310.
37. Goetz MB, Boscardin WJ, Wiley D, Alkasspooles S (2001) Decreased recovery of CD4 lymphocytes in older HIV-infected patients beginning highly active antiretroviral therapy. AIDS 15:1576-1579.
38. Golden PL, Pardridge WM (2000) Brain microvascular Pglycoprotein and a revised model of multidrug resistance in brain. Cell Mol Neurobiol 20:165-181.
39. Gollapudi S, Gupta S (1990) Human immunodeficiency virus I-induced expression of P-glycoprotein. Biochem Biophys Res Commun 171:1002-1007.
40. Goodkin K, Wilkie FL, Concha M, Hinkin CH, Symes S, Baldewicz TT, Asthana D, Fujimura RK, Lee D, van Zuilen MH et al (2001) Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality. J Clin Epidemiol 54 Suppl 1:S35-43.
41. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
42. Gray F, Adle-Biassette H, Chretien F, Lorin de la Grandmaison G, Force G, Keohane C (2001) Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments. Clin Neuropathol 20:146-155.
43. Gray F, Belec L, Keohane C, De Truchis P, Clair B, Durigon M, Sobel A, Gherardi R (1994) Zidovudine therapy and HIV encephalitis: a 10-year neuropathological survey. AIDS 8:489-493.
44. Harrold SM, Wang G, McMahon DK, Riddler SA, Mellors JW, Becker JT, Caldararo R, Reinhart TA, Achim CL, Wiley CA (2002) Recovery of replication-competent HIV type 1-infected circulating monocytes from individuals receiving antiretroviral therapy. AIDS Res Hum Retroviruses 18:427-434.
45. Hoffmann C, Jaeger H (2001) Cardiology and AIDS HAART and the consequences. Ann NY Acad Sci 946:130-144.
46. Hong M, Schlichter L, Bendayan R (2001) A novel zidovudine uptake system in microglia. J Pharmacol Exp Ther 296:141-149.
47. Irlbeck D, Stanhope, M.J., Douady, C., Amrine, H.M., Melby, T., McCLernon, D.R., Lanier, E.R. Phylogenetic analyses of HIV-1 from an AIDS Dementia patient suggest compartmentalized evolution in the mid-frontal gyrus of the brain. XI International Workshop on Drug Resistance and Treatment Strategies. Seville, Spain 2002.
48. Jamieson DG, Usher DC, Rader DJ, Lavi E (1995) Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation. Am J Pathol 147:1567-1574.
49. Janssen RS, Nwanyanwu OC, Selik RM, Stehr-Green JK (1992) Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology 42:1472-1476.
50. Jellinger KA, Setinek U, Drlicek M, Bohm G, Steurer A, Lintner F (2000) Neuropathology and general autopsy findings in AIDS during the last 15 years. Acta Neuropathol (Berl) 100:213-220.
51. Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA, Back DJ (2001) P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 15:1353-1358.
52. Jones S, Klotman ME (2001) Impact of genotypic resistance testing on physician selection of antiretrovirai therapy. J Hum Virol 4:214-216.
53. Jorajuria S, Clayette P, Dereuddre-Bosquet N, Larghero J, Thiebot H, Neildez O, Vaslin B, Le Grand R, Dormont D (2000) [Evaluation of the effect of early and massive tritherapy on the expression of cellular factors potentially implicated in antiretroviral therapy resistance]. Pathol Biol (Paris) 48:490-494.
54. Jordan-Sciutto KL, Wang G, Murphey-Corb M, Wiley CA (2002) Cell cycle proteins exhibit altered expression patterns in lentiviral-associated encephalitis. J Neurosci 22:2185-2195.
55. Kim AE, Dintaman JM, Waddell DS, Silverman JA (1998) Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 286:1439-1445.
56. Kim B, Lyons TM, Parada JP, Uphold CR, Yarnold PR, Hounshell JB, Sipler AM, Goetz MB, DeHovitz JA, Weinstein RA et al (2001) HIV-related Pneumocystis carinii pneumonia in older patients hospitalized in the early HAART era. J Gen Intern Med 16:583-589.
57. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
58. Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, Hicklin D, Kerbel RS (2002) Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 8:221-232.
59. Klint P, Kanda S, Kloog Y, Claesson-Welsh L (1999) Contribution of Src and Ras pathways in FGF-2 induced endothelial cell differentiation. Oncogene 18:3354-3364.
60. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM (1992) Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258:1798-1801.
61. Kusdra L, McGuire D, Pulliam L (2002) Changes in monocyte/macrophage neurotoxicity in the era of HAART: implications for HIV-associated dementia. AIDS 16:31-38.
62. Lackner A, Smith M, Munn R, Martfeld D, Gardner M, Marx P, Dandekar S (1991) Localization of simian immunodeficiency virus in the central nervous system of rhesus monkeys. Am J Pathol 139:609-621.
63. Langford D, Masliah E (2001) Crosstalk between components of the blood brain barrier and cells of the CNS in microglial activation in AIDS. Brain Pathol 11:306-312.
64. Langford TD, Letendre SL, Marcotte TD, Ellis RJ, McCutchan JA, Grant I, Mallory ME, Hansen LA, Archibald S, Jernigan T et al (2002) Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 16:1019-1029.
65. Lanier ER, Sturge G, McClernon D, Brown S, Halman M, Sacktor N, McArthur J, Atkinson JH, Clifford D, Price RW et al (2001) HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. AIDS 15:747-751.
66. Lee CG, Gottesman MM (1998) HIV-1 protease inhibitors and the MDR1 multidrug transporter. J Clin Invest 101:287-288.
67. Lee TH, Avraham H, Lee SH, Avraham S (2002) Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells. J Biol Chem 277:10445-10451.
68. Li S, Couet J, Lisanti MP (1996) Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem 271:29182-29190.
69. Li S, Okamoto T, Chun M, Sargiacomo M, Casanova JE, Hansen SH, Nishimoto I, Lisanti MP (1995) Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem 270:15693-15701.
70. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsberg HN, Sturley SL (2001) HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 7:1327-1331.
71. Limoges J, Poluektova L, Ratanasuwan W, Rasmussen J, Zelivyanskaya M, McClernon DR, Lanier ER, Gendelman HE, Persidsky Y (2001) The efficacy of potent anti-retroviral drug combinations tested in a murine model of HJV-1 encephalitis. Virology 281:21-34.
72. Liu P, Ying Y, Anderson RG (1997) Platelet-derived growth factor activates mitogen-activated protein kinase in isolated caveolae. Proc Natl Acad Sci U S A 94:13666-13670.
73. Liu Y, Tang XP, McArthur JC, Scott J, Gartner S (2000) Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J Neurovirol 6 Suppl 1:S70-81.
74. Lucia MB, Rutella S, Leone G, Vella S, Cauda R (2001) HIV- protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. J Acquir Immune Defic Syndr 27:321-330.
75. Maehlen J, Dunlop O, Liestol K, Dobloug JH, Goplen AK, Torvik A (1995) Changing incidence of HIV-induced brain lesions in Oslo, 1983-1994: effects of zidovudine treatment. AIDS 9:1165-1169.
76. Mahieux R, Lambert PF, Agbottah E, Halanski MA, Deng L, Kashanchi F, Brady JN (2001) Cell cycle regulation of human interleukin-8 gene expression by the human immunodeficiency virus type 1 Tat protein. J Virol 75:1736-1743.
77. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A et al (2001) Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357:592-598.
78. Masliah E, Achim C, Ge N, DeTeresa R, Terry R, Wiley C (1992) Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol 32:321-329.
79. Masliah E, DeTeresa R, Mallory M, Hansen L (2000) Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS 14:69-74.
80. Masliah E, Ge N, Achim C, DeTeresa R, Wiley C (1996) Patterns of neurodegeneration in HIV encephalitis. NeuroAIDS 1: 161 -173.
81. Masliah E, Heaton R, Marcotte T, Ellis R, Wiley C, Mallory M, Achim C, McCutchan A, Nelson J, Atkinson H et al (1997) Dendritic injury is a pathological substrate for human immunodefficiency virus-related cognitive disorders. Ann Neurol 42:963-972.
82. McArthur J, Hoover D, Bacellar H, Miller E, Cohen B, Becker J, Graham N, McArthur J, Selnes O, Jacobson L et al (1993) Dementia in AIDS patients: incidence and risk factors. Neurology 43:2245-2252.
83. Mineo C, James GL, Smart EJ, Anderson RG (1996) Localization of epidermal growth factor-stimulated Ras/Raf-1 interaction to caveolae membrane. J Biol Chem 271:11930-11935.
84. Morris L, Silber E, Sonnenberg P, Eintracht S, Nyoka S, Lyons S, Saffer D, Koornhof H, Martin D (1998) High human immunodeficiency virus type 1 RNA load in the cerebrospinal fluid from patients with lymphocytic meningitis. J Inf Dis 177:473-476.
85. Moyle G (2000) Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 22:911-936; discussion 898.
86. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, Lo JC, Schambelan M (2000) Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 23:35-43.
87. Nguyen AT, Gagnon A, Angel JB, Sorisky A (2000) Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. AIDS 14:2467-2473.
88. Nottet H, Persidsky Y, Sasseville V, Nukuna A, Bock P, Zhai Q, Sharer L, McComb R, Swindells S, Soderland C et al (1996) Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunol 156:1284-1295.
89. O'Driscoll G, Green D, Taylor RR (1997) Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95:1126-1131
90. Ohara Y, Peterson TE, Harrison DG (1993) Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91:2546-2551.
91. Oka N, Yamamoto M, Schwencke C, Kawabe J, Ebina T, Ohno S, Couet J, Lisanti MP, Ishikawa Y (1997) Caveolin interaction with protein kinase C. Isoenzyme-dependent regulation of kinase activity by the caveolin scaffolding domain peptide. J Biol Chem 272:33416-33421.
92. Orandle MS, MacLean AG, Sasseville VG, Alvarez X, Lackner AA (2002) Enhanced expression of proinflammatory cytokines in the central nervous system is associated with neuroinvasion by simian immunodeficiency virus and the development of encephalitis. J Virol 76:5797-5802.
93. Pan-Zhou XR, Cui L, Zhou XJ, Sommadossi JP, DarleyUsmar VM (2000) Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrob Agents Chemother 44:496-503.
94. Persidsky Y, Ghorpade A, Rasmussen J, Limoges J, Liu X, Stins M, Fiala M, Way D, Kim K, Witte M et al (1999) Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. Am J Pathol 155:1599-1611.
95. Persidsky Y, Stins M, Way D, Witte M, Weinand M, Kim K, Bock P, Gendelman H, Fala M (1997) A model of monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J Immunol 158:3499-3510.
96. Pohlman TH, Harlan JM (2000) Adaptive responses of the endothelium to stress. J Surg Res 89:85-119.
97. Power C, Gill MJ, Johnson RT (2002) Progress in clinical neurosciences: the neuropathogenesis of HIV infection: host-virus interaction and the impact of therapy. Can J Neurol Sci 29:19-32.
98. Price RW, Paxinos EE, Grant RM, Drews B, Nilsson A, Hoh R, Hellmann NS, Petropoulos CJ, Deeks SG (2001) Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS 15:1251-1259.
99. Rader DJ, Dugi KA (2000) The endothelium and lipoproteins: insights from recent cell biology and animal studies. Semin Thromb Hemost 26:521-528.
100. Raulin J (2002) Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy. Prog Lipid Res 41:27-65.
101. Resnick L, Berger J, Shapshak P, Tourtellotte W (1988) Early penetration of the blood-brain-barrier by HIV. Neurology 38:9-14.
102. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, Becker JT, Cohen B, McArthur JC (2001) HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 56:257-260.
103. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K et al (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136-142.
104. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR, Kleinman HK, Murphy WJ, Oppenheim JJ (1999) Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neurovascularization induced by stromal-derived factor-1 alpha. Am J Pathol 154:1125-1135.
105. Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, Tosato G (2002) Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 99:2703-2711.
106. Shelburne SA, 3rd, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, Gathe JC, Jr., Visnegarwala F, Trautner BW (2002) Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 81:213-227.
107. Shi B, De Girolami U, He J, Wang S, Lorenzo A, Busciglio J, Gabuzda D (1996) Apoptosis induced by HIV-1 infection of the central nervous system. J Clin Invest 98:1979-1990.
108. Smith KY (2002) Selected metabolic and morphologic complications associated with highly active antiretroviral therapy. J Infect Dis 185 Suppl 2:S123-127.
109. Sobue K, Yamamoto N, Yoneda K, Hodgson M, Yamashiro K, Tsuruoka N, Katsuya H, Miura Y, Asai K, Kato T (1999) Induction of bloodbrain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors. Neurosci Res 35:155-164.
110. Sporer B, Koedel U, Paul R, Kohleisen B, Erfle V, Fontana A, Pfister H (2000) Human immunodeficiency virus type-1 Nef protein induces blood-brain barrier disruption in the rat: role of matrix metalloproteinase-9. J Neuroimmunol 102:125-130.
111. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, Sosman JM (2001) Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104:257-262.
112. Steinberg D (1991) Antioxidants and atherosclerosis. A current assessment. Circulation 84:1420-1425.
113. Stern Y, McDermott MP, Albert S, Palumbo D, Selnes OA, McArthur J, Sacktor N, Schifitto G, Kieburtz K, Epstein L et al (2001) Factors associated with incident human immunodeficiency virus-dementia. Arch Neurol 58:473-479.
114. Strelow LI, Watry DD, Fox HS, Nelson JA (1998) Efficient infection of brain microvascular endothelial cells by an in vivo-selected neuroinvasive SIVmac variant. J Neurovirol 4:269-280.
115. Suarez S, Baril L, Stankoff B, Khellaf M, Dubois B, Lubetzki C, Bricaire F, Hauw JJ (2001) Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy. AIDS 15:195-200.
116. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84:7735-7738.
117. Turriziani O, Antonelli G, Dianzani F (2000) Cellular factors involved in the induction of resistance of HIV to antiretroviral agents. Int J Antimicrob Agents 16:353-356.
118. van Praag RM, Weverling GJ, Portegies P, Jurriaans S, Zhou XJ, Turner-Foisy ML, Sommadossi JP, Burger DM, Lange JM, Hoetelmans RM et al (2000) Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 14:1187-1194.
119. Wartenberg M, Donmez F, Ling FC, Acker H, Hescheler J, Sauer H (2001) Tumor-induced angiogenesis studied in confrontation cultures of multicellular tumor spheroids and embryoid bodies grown from pluripotent embryonic stem cells. Faseb J 15:995-1005.
120. White DA, Heaton RK, Monsch AU (1995) Neuropsychological studies of asymptomatic human immunodeficiency virus-type-1 infected individuals. The HNRC Group. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1:304-315.
121. Xiao H, Neuveut C, Tiffany HL, Benkirane M, Rich EA, Murphy PM, Jeang KT (2000) Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci U S A 97:11466-11471.
122. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA et al (2002) Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288:222-235.
123. Yozviak JL, Doerfler RE, Woodward WC (2002) Resuppression of virus load after interruption in treatment with nevirapine and 2 nucleoside reverse-transcriptase inhibitors. Clin Infect Dis 34:547-550.
124. Zaera MG, Miro O, Pedrol E, Soler A, Picon M, Cardellach F, Casademont J, Nunes V (2001) Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS 15:1643-1651.